Product Overview
Our OsteoSurge® 100 grafts combine demineralized bone matrix with patented Accell® bone matrix in a bioresorbable, reverse phase medium carrier. Provided in a syringe, the putty is moldable and resists irrigation. The putty may be implanted directly from the syringe.
Key Features
Accell Technology - The patented Accell process yields Accell bone matrix (ABM). ABM is an open-structured, dispersed form of DBM.
Superior Handling - The unique, poloxamer, reverse phase medium carrier, which becomes more viscous at body temperature, provides exceptional handling and containment characteristics. The graft is moldable, packable, mixable and resists irrigation.
Verified Osteoinductive Potential - Every lot of DBM is tested in a validated, in vitro assay to verify osteoinductive potential.
Expert Processing - Ground cortical bone and cancellous bone obtained from AATB-accredited tissue banks is processed into DBM in our state-of-the-art facility. The demineralization process is tightly controlled to consistently produce demineralized bone.
Electron Beam Sterilization - The processing of DBM and ABM is completed under aseptic conditions in our state-of-the-art facility. As the last step in manufacturing, the graft is sterilized via electron beam irradiation.
Indications:
OsteoSurge™ 100 is intended for filling voids and gaps in the skeletal system that are not intrinsic to the stability of the bony structure. OsteoSurge 100 is indicated for use as a bone graft extender in the spine, extremities and pelvis, or as a bone void filler in the extremities and pelvis. The voids or gaps may be surgically created defects or the result of traumatic injury to the bone. (https://www.seaspine.com/)
